Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema vs semaglutide vs cagrilintide vs placebo in CKD with type 2 diabetes and obesity
2023-505857-42-00Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2024
- Modality
- Peptides
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of CagriSema in chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and 1 more (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change in UACR from baseline to end of treatment. Started Apr 2024; status: completed.
02
Drugs
CagriSema
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on 2023-505857-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505857-42-00.